期刊文献+

Feasibility and efficacy evaluation of metallic biliary stents eluting gemcitabine and cisplatin for extrahepatic cholangiocarcinoma 被引量:9

在线阅读 下载PDF
导出
摘要 BACKGROUND Effective endoscopic management is fundamental for the treatment of extrahepatic cholangiocarcinoma(ECC).However,current biliary stents that are widely used in clinical practice showed no antitumor effect.Drug-eluting stents(DESs)may achieve a combination of local chemotherapy and biliary drainage to prolong stent patency and improve prognosis.AIM To develop novel DESs coated with gemcitabine(GEM)and cisplatin(CIS)-coloaded nanofilms that can maintain the continuous and long-term release of antitumor agents in the bile duct to inhibit tumor growth and reduce systemic toxicity.METHODS Stents coated with different drug-eluting components were prepared by the mixed electrospinning method,with poly-L-lactide-caprolactone(PLCL)as the drug-loaded nanofiber membrane and GEM and/or CIS as the antitumor agents.Four different DESs were manufactured with four drug-loading ratios(5%,10%,15%,and 20%),including bare-loaded(PLCL-0),single-drug-loaded(PLCL-GEM and PLCL-CIS),and dual-drug-loaded(PLCL-GC)stents.The drug release property,antitumor activity,and biocompatibility were evaluated in vitro and in vivo to confirm the feasibility and efficacy of this novel DES for ECC.RESULTS The in vitro drug release study showed the stable,continuous release of both GEM and CIS,which was sustained for over 30 d without an obvious initial burst,and a higher drug-loaded content induced a lower release rate.The drug-loading ratio of 10%was used for further experiments due to its ideal inhibitory efficiency and relatively low toxicity.All drug-loaded nanofilms effectively inhibited the growth of EGI-1 cells in vitro and the tumor xenografts of nude mice in vivo;in addition,the dual-loaded nanofilm(PLCL-GC)had a significantly better effect than the single-drug-loaded nanofilms(P<0.05).No significant differences in the serological analysis(P>0.05)or histopathological changes were observed between the single-loaded and drug-loaded nanofilms after stent placement in the normal porcine biliary tract.CONCLUSION This novel PLCL-GEM and CIS-eluting stent maintains continuous,stable drug release locally and inhibits tumor growth effectively in vitro and in vivo.It can also be used safely in normal porcine bile ducts.We anticipate that it might be considered an alternative strategy for the palliative therapy of ECC patients.
出处 《World Journal of Gastroenterology》 SCIE CAS 2020年第31期4589-4606,共18页 世界胃肠病学杂志(英文版)
基金 Supported by the National Natural Science Foundation of China,No.81870452 and No.81470904 Science and Technology Development Funds of Shanghai of China,No.16411952400.
  • 相关文献

参考文献1

二级参考文献20

  • 1Dhakshinamoorthy Ganeshan,Fanny E Moron,Janio Szklaruk,.Extrahepatic biliary cancer:New staging classification[J].World Journal of Radiology,2012,4(8):345-352. 被引量:5
  • 2Lim JH.Cholangiocarcinoma: morphologic classification according to growth pattern and imaging findings. American Journal of Roentgenology . 2003
  • 3W.R. Jarnagin,M. Shoup.Surgical management of cholangiocarcinoma. Seminars in Liver Disease . 2004
  • 4Friman S.Cholangiocarcinoma--current treatment options. Scand J Surg . 2011
  • 5HR Shin,JK Oh,E Masuyer,MP Curado,V Bouvard,Y Fang.Comparison of incidence of intrahepatic and extrahepatic cholangiocarcinoma—focus on East and South-eastern Asia. Asian Pacific Journal of Cancer Prevention . 2010
  • 6Khan SA,Emadossadaty S,Ladep NG,Thomas HC,Elliott P,Taylor-Robinson SD,Toledano MB.Rising trends in cholangiocarcinoma: is the ICD classification system misleading us. Journal of Hepatology . 2012
  • 7TM Welzel,BI Graubard,HB El-Serag,YH Shaib,AW Hsing,JA Davila,KA McGlynn.Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case–control study. Clinics in Gastroenterology . 2007
  • 8Tyson GL,El-Serag HB.Risk factors for cholangiocarcinoma. Hepatology . 2011
  • 9Blanchacz BR,,Gores GJ.Cholangiocarcinoma. Clinics in Liver Disease . 2008
  • 10Wu Q,He XD,Yu L,et al.The metabolic syndrome and risk fac tors for biliary tract cancer:a case-control study in China. Asian Pacific Journal of Cancer Prevention . 2012

共引文献23

同被引文献76

引证文献9

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部